196
Views
22
CrossRef citations to date
0
Altmetric
Original Article

Evaluation of levalbuterol metered dose inhaler in pediatric patients with asthma: a double-blind, randomized, placebo- and active-controlled trial

, , , , , & show all
Pages 1217-1226 | Accepted 25 Apr 2006, Published online: 19 May 2006

References

  • DeFrances CJ, Hall MJ, Podgornik MN. 2003 National Hospital Discharge Survey. Advance data from vital and health statistics; no 359. Hyattsville (MD): National Center for Health Statistics; 2005
  • National Institutes of Health. Guidelines for the diagnosis and management of asthma. NIH Publication 97–4051 1997:1–152
  • White MV, Sander N. Asthma from the perspective of the patient. J Allergy Clin Immunol 1999;104:S47–S52
  • Penn RB, Frielle T, McCullough JR, et al. Comparison of R-, S-, and RS-albuterol interaction with human b1- and b2-adrenergic receptors. Clin Rev Allergy Immunol 1996;14:37–45
  • Hartley D, Middlemiss D. Absolute configuration of the optical isomers of salbutamol. J Med Chem 1971;14:7–36
  • Agrawal DK, Ariyarathna K, Kelbe PW. (S)-albuterol activates proconstrictory and pro-inflammatory pathways in human bronchial smooth muscle cells. J Allergy Clin Immunol 2004;113:503–10
  • Ameredes BT, Calhoun WJ. Modulation of GM-CSF-release by enantiomers of b-agonists in human airway smooth muscle. J Allergy Clin Immunol 2005;116:65–72
  • Cho SH, Hartleroad JY, Oh CK. (S)-Albuterol increases the production of histamine and IL-4 mast cells. Int Arch Allergy Immunol 2001;124: 478–84
  • Baramki D, Koester J, Anderson AJ, et al. Modulation of t-cell function by (R)- and (S)-isomers of albuterol: anti-inflammatory influences of (R)-isomers are negated in the presence of the (S)-isomer. J Allergy Clin Immunol 2002;108:449–54
  • Xopenex Inhalation Solution [package insert]. Marlborough, MA: Sepracor Inc.; 2005
  • Gawchik SM, Saccar CL, Noonan M, et al. The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. J Allergy Clin Immunol 1999;103:615–21
  • Milgrom H, Skoner DP, Bensch G, et al. Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol. J Allergy Clin Immunol 2001;108:938–45
  • Nelson HS, Bensch G, Pleskow WW, et al. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol 1998;102:943–52
  • Pleskow WW, Nelson HS, Schaefer K, et al. Pairwise comparison of levalbuterol versus racemic albuterol in the treatment of moderate-to-severe asthma. Allergy Asthma Proc 2004;25:429–36
  • Carl JC, Myers TR, Kirchner LH, Kercsmar CM. Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. J Pediatrics 2003;143:731–6
  • Schreck DM, Babin S. Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED. Am J Emerg Med 2005;23:842–7
  • Qureshi F, Zaritsky, A, Welch C, et al. Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma. Ann Emerg Med 2005;46:29–36
  • Berger WE. Paediatric pulmonary drug delivery: considerations in asthma treatment. Expert Opin Drug Deliv 2005;2: 965–80
  • World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. J Am Med Assoc 1997;277:925–6
  • American Thoracic Society. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med 1995;152: 1107–56
  • Juniper EF, Guyatt GH, Feeny DH, et al. Measuring quality of life in children with asthma. Qual Life Res 1996;5:35–46
  • Landgraf JM, Abetz L, Ware JE. Child Health Questionnaire (CHQ): a user’s manual. The Health Institute, New England Medical Center, Boston, MA
  • Nowak R. Single-isomer levalbuterol: a review of the acute data. Current Allergy Asthma Reports 2003;3:172–8
  • Berger WE. Levalbuterol: pharmacologic properties and use in the treatment of pediatric and adult asthma. Ann Allergy Asthma Immunol 2003;90:583–92
  • Ahrens R, Weinberger M. Levalbuterol and racemic albuterol: are there therapeutic differences? J Allergy Clin Immunol 2001;108:681–4
  • Asmus MJ, Hendeles L, Weinberger M, et al. Levalbuterol has not been established to have therapeutic advantages over racemic albuterol. J Allergy Clin Immunol 2002;100:325
  • Chowdhury BA. Comparative efficacy of levalbuterol and racemic albuterol in the treatment of asthma. J Allergy Clin Immunol 2002;110:324
  • Eaton EA, Waller UK, Wilson HM, et al. Stereoselective sulphate conjugation of salbutamol by human lung and bronchial epithelial cells. Br J Clin Pharmacol 1996;41:35–40
  • Boulton DW, Fawcett JP. Enantioselective disposition of salbutamol in man following oral and intravenous administration. Br J Clin Pharmacol 1996;41:35–40
  • Dhand R, Goode M, Reid R, et al. Preferential pulmonary retention of (S)-albuterol after inhalation of racemic albuterol. Am J Respir Crit Care Med 1999;160:1136–41
  • Henderson WR, Banerjee ER, Chi EY. Differential effects of (S)- and (R)-enantiomers of albuterol in a mouse asthma model. J Allergy Clin Immmunol 2005;116:332–40
  • Nowak R, Emerman C, Hanrahan JP, et al. A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults. Am J Emerg Med 2006;24:259–67

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.